X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the divestment, Mundipharma received the rights for Rezzayo (rezafungin acetate), an echinocandin antifungal, approved for the treatment of invasive candidiasis in adults.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Rezzayo
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Cidara Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Divestment April 24, 2024
Details:
The two companies have entered into a collaboration agreement to continue the development work of incorporating an environmentally friendly propellant into the formulation of flutiform® (fluticasone propionate/formoterol fumarate) used in a pMDI.
Lead Product(s): Fluticasone Propionate,Formoterol Fumarate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Flutiform
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Vectura Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 16, 2024
Details:
The payment triggered under the agreement is following the European approval of Rezzayo (rezafungin acetate), a novel, once-weekly echinocandin antifungal approved for the treatment of invasive candidiasis in adults.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Rezzayo
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: Cidara Therapeutics
Deal Size: $568.0 million Upfront Cash: $39.0 million
Deal Type: Partnership February 12, 2024
Details:
Rezzayo (rezafungin) is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Rezzayo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2023
Details:
Rezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as invasive candidiasis and candidemia.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Rezzayo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cidara Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2023
Details:
CD101 (rezafungin) is a novel, once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections,demonstrated non-inferiority to the current standard of care in the treatment of candidemia and/or invasive candidiasis.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: CD101
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2022
Details:
Rezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: CD101
Highest Development Status: Phase IIIProduct Type: Peptide
Recipient: Cidara Therapeutics
Deal Size: $568.0 million Upfront Cash: $30.0 million
Deal Type: Licensing Agreement October 04, 2022
Details:
European Medicines Agency filing is supported by the pivotal ReSTORE Phase III clinical trial results, where rezafungin (echinocandin/CD101) demonstrated non-inferiority to the current standard of care, caspofungin in the treatment of candidemia and/or invasive candidiasis.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: CD101
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
Results from ReSTORE showed primary endpoints were met with, 23.7% all-cause mortality on day 30 for rezafungin compared to 21.3% for caspofungin global cure on day 14 of 59.1% for rezafungin and 60.6% for caspofungin.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: CD101
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Cidara Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2022
Details:
Result, did not demonstrate highly potent antifungal properties of CD101 against Candida in preclinical animal models of VVC, CD101 IV has enhanced potency and is only once-weekly therapy intended for treatment and prevention of life-threatening invasive fungal infections.
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: CD101
Highest Development Status: Phase IIIProduct Type: Peptide
Recipient: Cidara Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
